Literature DB >> 15980881

Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders.

H Bittencourt1, V Rocha, A Filion, I Ionescu, A-L Herr, F Garnier, L Ades, H Esperou, A Devergie, P Ribaud, G Socie, E Gluckman.   

Abstract

Poor graft function (PGF) is a frequent cause of morbidity after allogeneic hematopoietic stem cell transplantation (allo-HSCT). To study the value of granulocyte colony-stimulating factor (G-CSF) in PGF, we retrospectively analyzed 81 episodes of PGF in 66 patients transplanted from 01/94 to 01/99 from an HLA-identical sibling (n = 45) or an unrelated (n = 21) donor. Median age was 29 years, 55 patients had malignancies. A total of 11 patients received a CD34+ selected graft. Viral infections (25%), myelotoxic drug (33%), fungal/bacterial infections (14%), and GVHD (31%) were present before PGF diagnosis. Median time from allo-HSCT to PGF was 75 (25-474) days. All patients were treated with G-CSF. In 77/81 episodes, there was a response that was sustained in 57. A total of 27 patients presented an increase of white cell count (WBC) >0.1 x 10(9)/l after 3 days of G-CSF. The 5-year survival was 37% and was significantly better in patients with increased WBC > 0.1 x 10(9)/l after 3 days of G-CSF (65 vs 18%, P < 0.0001). In multivariate analysis, increased WBC > 0.1 x 10(9)/l after 3 days of G-CSF (P = 0.002) was associated with better survival, while BuCy-based conditioning (P = 0.02) and GVHD (P = 0.005) were associated with higher risk of death. In conclusion, hematological response after 3 days with G-CSF predicted a better survival for patients with PGF after allo-SCT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15980881     DOI: 10.1038/sj.bmt.1705072

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

1.  Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation.

Authors:  Sebastian P Haen; Michael Schumm; Christoph Faul; Lothar Kanz; Wolfgang A Bethge; Wichard Vogel
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-14       Impact factor: 4.553

2.  Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies.

Authors:  Sebastian P Haen; Vicky Eyb; Nora Mirza; Aline Naumann; Andreas Peter; Markus W Löffler; Christoph Faul; Wichard Vogel; Wolfgang A Bethge; Hans-Georg Rammensee; Lothar Kanz; Martin Heni
Journal:  J Cancer Res Clin Oncol       Date:  2017-02-16       Impact factor: 4.553

3.  Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs.

Authors:  Hirohisa Nakamae; Barry Storer; Brenda M Sandmaier; David G Maloney; Chris Davis; Lawrence Corey; Rainer Storb; Michael Boeckh
Journal:  Haematologica       Date:  2011-08-31       Impact factor: 9.941

4.  Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag.

Authors:  Cen Tang; Feng Chen; Danqing Kong; Qinfen Ma; Haiping Dai; Jia Yin; Zheng Li; Jia Chen; Xiaming Zhu; Xinliang Mao; Depei Wu; Xiaowen Tang
Journal:  J Hematol Oncol       Date:  2018-08-16       Impact factor: 17.388

5.  Haploidentical donor transplant is associated with secondary poor graft function after allogeneic stem cell transplantation: A single-center retrospective study.

Authors:  Wei-Ran Lv; Ya Zhou; Jun Xu; Zhi-Ping Fan; Fen Huang; Na Xu; Li Xuan; Peng-Cheng Shi; Hui Liu; Zhi-Xiang Wang; Jing Sun; Qi-Fa Liu
Journal:  Cancer Med       Date:  2021-10-20       Impact factor: 4.452

6.  Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation.

Authors:  Yang Xiao; Jiayin Song; Zujun Jiang; Yonghua Li; Yang Gao; Wenning Xu; Ziyuan Lu; Yaochun Wang; Haowen Xiao
Journal:  Int J Med Sci       Date:  2014-04-30       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.